<DOC>
	<DOC>NCT02363439</DOC>
	<brief_summary>An extension study for patients who complete 24 weeks of IMO-8400 on study 8400-401.</brief_summary>
	<brief_title>Extension Study of IMO-8400 in Patients With Waldenstr√∂m's Macroglobulinemia Who Completed Study 8400-401</brief_title>
	<detailed_description>Patients who had no evidence of disease progression or toxicity while participating in study 8400-401 will continue to receive IMO-8400 until disease progression, adverse event or the investigator deems the goals of extended treatment with IMO-8400 have been met.</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>Completed 24 weeks of treatment in Protocol 8400401 Grade 3 (or higher) adverse event assessed as treatmentrelated at any time during the course of treatment under Protocol 8400401. Has evidence of disease progression under Protocol 8400401. Has received other anticancer therapies other than IMO8400 since enrolling in Protocol 8400401.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>